Expertise in
3
conditions

Zhimin J. Shao

270 Dong An Road, 
Shanghai, CN 
Expertise in
3
conditions
270 Dong An Road, 
Shanghai, CN 

Overview

Zhimin Shao practices practicing medicine in Shanghai, China.

Shao is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Metastatic Brain Tumor, Alternating Hemiplegia of Childhood, and Mastectomy.

They are actively involved in clinical research, co-authoring 162 peer reviewed articles and participating in 5 clinical trials.

Locations

270 Dong An Road, Shanghai, 200032, China
Other Locations
Dong'an Road 270, Shanghai, China
138 Yi Xue Yuan Road, Xuhui, 200032, China
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL1209/Pertuzumab in Combination With Docetaxel in Patients With Early-Stage or Locally Advanced HER2-Positive and ER/PR-negative Breast Cancer.
A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL1209/Pertuzumab in Combination With Docetaxel in Patients With Early-Stage or Locally Advanced HER2-Positive and ER/PR-negative Breast Cancer.
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, QL1209, Pertuzumab, Docetaxel
Study Phase: Phase 3
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
Enrollment Status: Unknown
Publish Date: November 29, 2021
Intervention Type: Drug
Study Drugs: AI adjuvant therapy, Chemotherapy
Study Phase: Phase 2
Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old
Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old
Enrollment Status: Completed
Publish Date: May 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
Fluorine-18 Fluoroestradiol Positron Emission Tomography-computed Tomography: an in Vivo Biomarker Predicting Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer?
Fluorine-18 Fluoroestradiol Positron Emission Tomography-computed Tomography: an in Vivo Biomarker Predicting Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer?
Enrollment Status: Completed
Publish Date: May 08, 2019
Intervention Type: Drug
Study Phase: Not Applicable
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Enrollment Status: Unknown
Publish Date: April 19, 2017
Intervention Type: Drug
Study Drugs: 5-Fu/Epirubicin/CTX Following Docetaxel, Docetaxel/Capecitabine Followed by Capecitabine/Epirubicin/Cyclophosphamide
Study Phase: Phase 3
View 4 Less Clinical Trials

162 Total Publications

Early identification of PRISm from chest CT: a multimodal for three-class stratification of normal, PRISm, and COPD.
Early identification of PRISm from chest CT: a multimodal for three-class stratification of normal, PRISm, and COPD.
Journal: Frontiers in radiology
Published: March 13, 2026

Frequently Asked Questions about Zhimin J. Shao

Is Zhimin J. Shao a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Zhimin J. Shao is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zhimin J. Shao participate in research or clinical trials?

Yes. Zhimin J. Shao has published 162 articles and abstracts on conditions like Breast Cancer. You can view a list of Zhimin J. Shao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shao's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile